Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights
- Recent initiation of STAR phase 3 trial in Choroideremia - - Begins 2018 with a cash position over $129 million - LEXINGTON, Mass. and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy …